-
Talk to Us: info@nidccglobal.org
-
Location: Washington, DC | Abuja, Nigeria
Language:
Everyday Economic News
Tuttle Capital's Concentrated Memory Stack ETF (HBMX) Adds Exposure to CXMT, the $488 Billion Chinese Memory Maker Many U.S. Investors Can't Access Directly
Tuttle Capital's Concentrated Memory Stack ETF (HBMX) has added exposure to ChangXin Memory Technologies (CXMT), a Chinese memory chip producer valued at $488 billion after its recent Shanghai debut. CXMT, which is inaccessible to most U.S. investors directly due to its China A-share listing and lack of a U.S.-listed ADR, is now the world's fourth-largest DRAM producer. HBMX gains economic exposure through a total return swap, aiming to provide U.S. investors access to key players in the memory ecosystem, especially those difficult to reach.
SpaceX Stock Meltdown Takes $28 Billion Bite Out of Google's Portfolio
Alphabet's recent 13F filing revealed its public equity portfolio is dominated by a $94 billion stake in SpaceX (SPCX), following SpaceX's June IPO. While the filing showed a significant increase in Alphabet's portfolio value, a subsequent "meltdown" in SpaceX stock, losing 30% from its peak, has reduced Alphabet's paper gains by $28 billion. Despite this volatility, most of Alphabet's SpaceX shares are locked up, limiting near-term impact, but future 13F filings are expected to reflect significant changes based on SpaceX's stock performance.
BlossomHill Therapeutics shares fall in debut after IPO
BlossomHill Therapeutics Inc. (NASDAQ:BLSM) saw its shares fall 1.6% on Friday during its market debut, after the oncology-focused biotech firm raised $150 million in an upsized initial public offering. The stock opened at $15.75, below its IPO price of $16 per share. The company priced 9,375,000 shares at $16.00 each, resulting in gross proceeds of $150.0 million.
BlossomHill Therapeutics, Clinical-Stage Oncology Drug Developer, Files for Nasdaq Global Select Market IPO
BlossomHill Therapeutics, a clinical-stage biopharmaceutical company focused on oncology, has filed for an IPO on the Nasdaq Global Select Market under the ticker BLSM. The company plans to offer 9,375,000 shares at $16.00 each, aiming to raise $150 million. The proceeds will fund the advancement of its lead programs, BH-30643 for NSCLC, BH-30236 for AML/MDS, and BH-501284 for KRAS-mutant solid tumors, emphasizing its macrocyclic and structure-based drug design approach.
Latham & Watkins Advises on BlossomHill Therapeutics’ Upsized US$150 Million IPO
Latham & Watkins LLP advised the underwriters in BlossomHill Therapeutics, Inc.'s upsized initial public offering, which raised US$150 million. BlossomHill Therapeutics is a clinical-stage biopharmaceutical company focused on developing small molecule medicines for cancer treatment. The offering involved 9,375,000 shares of common stock priced at US$16.00 per share.
Banzai International, Inc. SEC Filing (Aug 7, 2026)
This article details an SEC filing by Banzai International, Inc. (BNZI) on August 7, 2026, which was a Notice of Effectiveness for Form S-1, indicating an effective date of August 6, 2026, at 4:30 P.M. The filing is noted as having a neutral impact and sentiment. The article also provides recent news and SEC filings related to Banzai International, Inc., including its plan to change its name to Parabolic Technologies, Inc., and the closing of a public offering.
KWESST MICRO SYSTEMS INC. (KWE) Announces November 7th IPO
KWESST MICRO SYSTEMS INC. (KWE) is set to raise $12 million through a unit offering and NASDAQ uplisting on the week of November 7th. The company plans to list its stock under the symbol "KWE" and warrants under "KWESW," issuing 2,300,000 shares at $4.13-$6.30 per share. KWESST, which generated $1.3 million in revenue and had a net loss of $9.3 million in the last fiscal year, develops next-generation technology solutions for military, public safety, and personal defense markets, focusing on non-lethal products, digitization, and counter-threat solutions.